Notice of Proposed Sale · 144
ARS Pharmaceuticals, Inc.
SPRYNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ARS PHARMACEUTICALS, INC.
- Issuer CIK
- 0001671858
- SEC file number
- 001-39756
- Phone
- (858) 771-9307
- Person for whose account securities are to be sold
- RICHARD LOWENTHAL
- Relationships to issuer
- Officer · Director · 10% Stockholder
- Street
- 11682 El Camino Real
- Street (continued)
- Suite 300
- City
- San Diego
- State / country code
- CA
- Postal code
- 92130
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 50,000 | 322,345.00 | 99,447,343 | 08/19/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/19/2026 | Stock Option Exercise | Issuer | 50,000 | N | 08/19/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| RICHARD LOWENTHAL | Common | 08/18/2026 | 50,000 | 315,885.00 |
Seller — prior-sale row 1, entry 1
- Name
- RICHARD LOWENTHAL
- Street
- 11682 El Camino Real
- Street (continued)
- Suite 300
- City
- San Diego
- State / country code
- CA
- Postal code
- 92130
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/19/2026
- Signed
- /s/ Richard E Lowenthal
Company context
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and UK), an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children aged 4 years and older who weigh 15 kg or greater. For more information, visit www.ars-pharma.com and follow us on LinkedIn and X.